Authors
Qing Li, Sanyang Liu, Mingyue Yao, Huimin Chen, Yangyang Yu, Baojia Zhang, Mingming Jia, Li Chen
Published in
iScience. Volume 29. Issue 11. Pages 118134. Nov 20, 2026. Epub Nov 05, 2026.
Abstract
Accurate peptide-HLA class I binding prediction is fundamental for identifying tumor neoantigens and advancing personalized immunotherapy. We present LKMHCpan, a pan-specific predictor that leverages transformer networks to optimize HLA-I pseudo-sequences representation through attention-guided integration of 88 key residues primarily within the α1, α2, and α3 domains. LKMHCpan achieves a mean precision-recall area under the curve (PR-AUC) of 0.93, generalizes robustly to untrained HLA-I alleles, and supports peptides longer than 11 amino acids. In Tumor Neoantigen Selection Alliance (TESLA) data, LKMHCpan identified 94% of immunogenic neoantigens with strong score-immunogenicity correlation. Neoantigen burden from LKMHCpan significantly stratified clinical outcomes in two immunotherapy-treated cohorts: metastatic melanoma (n = 73) and lung cancer (n = 309), with high-burden patients exhibiting clinical benefit. Its ability to resolve binding motifs for untrained alleles and single-amino-acid HLA-I mutants highlights its potential for elucidating complex peptide-major histocompatibility complex (MHC) interactions. LKMHCpan provides a scalable framework for neoantigen discovery and prognostic assessment in precision immunotherapy.
PMID:
43034688
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0